Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Materials Select Sector SPDR Fund — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B), while Materials Select Sector SPDR Fund trades at $50 (market cap $7.91B). The key difference: Materials Select Sector SPDR Fund is the larger of the two by market cap, and Materials Select Sector SPDR Fund is more actively traded (8,895,844 versus 2,060,842). Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Materials Select Sector SPDR Fund for 71 Days on average.
| TVTX | XLB | |
|---|---|---|
Market Cap | $5.02B | $7.91B |
Volume | 2,060,842 | 8,895,844 |
Sector | Health | — |
52-Week High | $67.52 | $53.67 |
52-Week Low | $26.79 | $42.23 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $5.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XLB trades at $49.72 with a modest 0.57% daily gain, though technical indicators signal a bearish trend with moving averages and key oscillators in sell or neutral territory. The materials ETF faces headwinds from sector concentration risks, with chemicals comprising 49% of assets. Recent news highlights both challenges from September's sector volatility and opportunities from infrastructure spending and AI-related demand.
The outlook remains cautious given technical weakness and sector cyclicality. While long-term infrastructure trends provide support, current valuations appear stretched with limited near-term catalysts. Key risks include China supply chain dependencies and economic sensitivity, requiring careful position sizing for materials exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
